HEMOGENYX PHARMPLC Market Capitalization vs. Total Debt
| 5HU Stock | EUR 3.79 0.01 0.26% |
For HEMOGENYX PHARMPLC profitability analysis, we use financial ratios and fundamental drivers that measure the ability of HEMOGENYX PHARMPLC to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well HEMOGENYX PHARMPLC LS 01 utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between HEMOGENYX PHARMPLC's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of HEMOGENYX PHARMPLC LS 01 over time as well as its relative position and ranking within its peers.
HEMOGENYX |
HEMOGENYX PHARMPLC Total Debt vs. Market Capitalization Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining HEMOGENYX PHARMPLC's current stock value. Our valuation model uses many indicators to compare HEMOGENYX PHARMPLC value to that of its competitors to determine the firm's financial worth. HEMOGENYX PHARMPLC LS 01 is rated below average in market capitalization category among its peers. It also is rated below average in total debt category among its peers making up about 0.07 of Total Debt per Market Capitalization. The ratio of Market Capitalization to Total Debt for HEMOGENYX PHARMPLC LS 01 is roughly 15.27 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the HEMOGENYX PHARMPLC's earnings, one of the primary drivers of an investment's value.HEMOGENYX Market Capitalization vs. Competition
HEMOGENYX PHARMPLC LS 01 is rated below average in market capitalization category among its peers. Market capitalization of Biotechnology industry is presently estimated at about 566.13 Billion. HEMOGENYX PHARMPLC adds roughly 24.89 Million in market capitalization claiming only tiny portion of stocks in Biotechnology industry.
HEMOGENYX Total Debt vs. Market Capitalization
Market Capitalization is the total market value of a company's equity. It is one of many ways to value a company and is calculated by multiplying the price of the stock by the number of shares issued. If a firm has one type of stock its market capitalization will be the current market share price multiplied by the number of shares. However, if a company has multiple types of equities then the market cap will be the total of the market caps of the different types of shares.
HEMOGENYX PHARMPLC |
| = | 24.89 M |
In most publications or references market cap is broken down into the mega-cap, large-cap, mid-cap, small-cap, micro-cap, and nano-cap. Market Cap is a measurement of business as total market value of all of the outstanding shares at a given time, and can be used to compare different companies based on their size.
Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
HEMOGENYX PHARMPLC |
| = | 1.63 M |
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
HEMOGENYX Total Debt vs Competition
HEMOGENYX PHARMPLC LS 01 is rated below average in total debt category among its peers. Total debt of Biotechnology industry is presently estimated at about 94.98 Billion. HEMOGENYX PHARMPLC adds roughly 1.63 Million in total debt claiming only tiny portion of stocks in Biotechnology industry.
HEMOGENYX PHARMPLC Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in HEMOGENYX PHARMPLC, profitability is also one of the essential criteria for including it into their portfolios because, without profit, HEMOGENYX PHARMPLC will eventually generate negative long term returns. The profitability progress is the general direction of HEMOGENYX PHARMPLC's change in net profit over the period of time. It can combine multiple indicators of HEMOGENYX PHARMPLC, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Hemogenyx Pharmaceuticals Plc, a preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood diseases. The company was incorporated in 2013 and is headquartered in London, the United Kingdom. HEMOGENYX PHARM is traded on Frankfurt Stock Exchange in Germany.
HEMOGENYX Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on HEMOGENYX PHARMPLC. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of HEMOGENYX PHARMPLC position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the HEMOGENYX PHARMPLC's important profitability drivers and their relationship over time.
Use HEMOGENYX PHARMPLC in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if HEMOGENYX PHARMPLC position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in HEMOGENYX PHARMPLC will appreciate offsetting losses from the drop in the long position's value.HEMOGENYX PHARMPLC Pair Trading
HEMOGENYX PHARMPLC LS 01 Pair Trading Analysis
The ability to find closely correlated positions to HEMOGENYX PHARMPLC could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace HEMOGENYX PHARMPLC when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back HEMOGENYX PHARMPLC - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling HEMOGENYX PHARMPLC LS 01 to buy it.
The correlation of HEMOGENYX PHARMPLC is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as HEMOGENYX PHARMPLC moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if HEMOGENYX PHARMPLC moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for HEMOGENYX PHARMPLC can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your HEMOGENYX PHARMPLC position
In addition to having HEMOGENYX PHARMPLC in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Consumer Funds Thematic Idea Now
Consumer Funds
Funds or Etfs that invest in consumer products such as packaged goods, clothing, food, beverages and retail services. The Consumer Funds theme has 46 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Consumer Funds Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in HEMOGENYX Stock
To fully project HEMOGENYX PHARMPLC's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of HEMOGENYX PHARMPLC at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include HEMOGENYX PHARMPLC's income statement, its balance sheet, and the statement of cash flows.